 |
 |
Dear Linda, I completely agree with your assertion that the research being conducted by Ceregene in no way dismisses the need for the reinstatement of GDNF treatment to the participants who have been involved in Amgen's clinical trial. I feel strongly that we should not abandon our efforts to convince Amgen to supply GDNF for further human clinical trials or else sell their patent to another company or institution who will allow the research to continue and I remain committed to participate in efforts to further that cause. I hope that my message did not convey feelings contrary to that mission. While I view Ceregene's work with Neurturin as one more avenue for investigation into treatment and hopefully a cure for Parkinson's and I'm encouraged and hopeful when I learn of efforts that might hold promise, I don't feel that this work negates, in any way, Amgen's responsibilities and the importance of GDNF to Parkinson's research. Thank you Linda, for your clarification on this matter....I know that we're on the same page here and I appreciate your input. Dee ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn